Observational studyArthritis research & therapy2025

The T-cell response to SARS-CoV- 2 vaccination persists beyond six months in rheumatoid arthritis patients treated with rituximab.

Juliette Marin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.